T-Cell engager – Talk Bio

Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile

1 week ago talkbio0Tagged benefit-risk profile, Clinical Trials, Dose-Limiting, Drug Development, Malignant Neoplasms, mesothelin, T-Cell engager, Toxicity aspects, ZW171, Zymeworks

Zymeworks; ZW171; T-cell engager; mesothelin; cancer; clinical trial; drug development; benefit-risk profile; dose-limiting toxicity

AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results

1 month ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Approved, Epcoritamab, EPKINLY, expansion, Genmab, Labels (device), lenalidomide, Lymphoma, Follicular, Phase 3 Clinical Trials, rituximab, T-Cell engager, United States Food and Drug Administration

Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 months ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships